Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dinesh Arab

Cardiovascular Disease Daytona Beach, FL Medical Doctor

NPI 1902843303 CMS profile 41567

103 Memorial Medical Pkwy Ste 200, Daytona Beach, FL 32117

Open in the dashboard

General payments

$107,230

936 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,123,858 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Dinesh Arab of Daytona Beach, FL is reported in the CMS Open Payments database as having received $107,230 across 936 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,123,858 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,754 85
2024 General $16,760 142
2023 General $14,613 131
2022 General $10,139 117
2021 General $5,893 115
2020 General $23,614 121
2019 General $29,456 225

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dinesh Arab
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Dinesh Arab were reported at $6,754. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Dinesh Arab Cardiovascular Disease median Middle half National median
2019 $29,456 $450 $127–$1,392 $163
2020 $23,614 $242 $77–$751 $114
2021 $5,893 $335 $101–$1,037 $132
2022 $10,139 $395 $121–$1,211 $149
2023 $14,613 $443 $136–$1,283 $160
2024 $16,760 $450 $136–$1,323 $164
2025 $6,754 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $38,246 80 payments
  2. Medtronic, Inc. $31,291 149 payments
  3. Cardiovascular Systems Inc. $10,937 62 payments
  4. CVRx, Inc. $8,085 79 payments
  5. Abbott Laboratories $6,131 69 payments
  6. Edwards Lifesciences Corporation $2,721 46 payments
  7. Boston Scientific Corporation $1,841 25 payments
  8. Janssen Pharmaceuticals, Inc $1,108 100 payments
  9. Abiomed $889 17 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $617 40 payments
  11. Other $5,364 269 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,131 29 payments
  2. Food and Beverage $21,694 847 payments
  3. Travel and Lodging $13,779 43 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $9,480 3 payments
  5. Consulting Fee $6,650 6 payments
  6. Education $495 8 payments
Products named General payments · program years 2019–2025
  1. CoreValve Evolut Transcatheter Valve Systems $38,162 74 payments
  2. COREVALVE EVOLUT R $26,582 110 payments
  3. Peripheral Orbital Atherectomy System $9,951 21 payments
  4. Barostim Neo System $8,085 79 payments
  5. CoreValve Evolut Transcatheter Valve Systems $3,707 15 payments
  6. AMPLATZER AMULET $3,284 20 payments
  7. WATCHMAN $1,210 11 payments
  8. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,187 11 payments
  9. XARELTO $1,108 100 payments
  10. Impella $889 17 payments
  11. Other $12,015 523 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

6,823

Median for Cardiology: 2,533

Drug cost

$2,458,513

Median for Cardiology: $485,213

Branded share of claims

38.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 650 $862,259
Repatha Sureclick Evolocumab Brand 224 $272,064
Xarelto Rivaroxaban Brand 225 $251,559
Entresto Sacubitril/Valsartan Brand 171 $222,643
Multaq Dronedarone Hcl Brand 146 $215,686
Camzyos Mavacamten Brand 19 $139,057
Jardiance Empagliflozin Brand 95 $121,132
Farxiga Dapagliflozin Propanediol Brand 81 $82,219
Repatha Syringe Evolocumab Brand 60 $77,935
Praluent Pen Alirocumab Brand 37 $34,023

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$1,389,899

Of which drugs: $17,543

Medicare patients

2,239

Average age 77

Services billed

11,029

1,097 women, 1,142 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 56%
Atrial fibrillation 44%
Chronic kidney disease 43%
Heart failure 37%
Diabetes 36%
COPD 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 313 1,246 $6,730

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
$72 — —
CAMZYOS
$54 19 —
JARDIANCE
$45 95 —
ELIQUIS
$33 650 —
NURTEC ODT
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

936 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record